

JOHN C. ANDREWS, PH.D. *Director of Regulatory Affairs, Americas*, Chiltern, a global CRO. For more information, visit chiltern.com.

JEROME BAILEY, *VP, Early Phase Business Center*, Omnicare Clinical Research, a full-service CRO with diverse therapeutic expertise and comprehensive clinical service offerings. For more information, visit omnicarecr.com.

HAL BARRON, *Global Head, Product Development and Chief Medical Officer*, Roche, a research-focused healthcare company with combined strengths in pharmaceuticals and diagnostics. For more information, visit rocheusa.com.

PATRICIA BASSETT, *VP Sales EMEA*, Unithink, a provider of solutions to pharmaceutical and biotech clients. For more information, visit unithink.com.

JOHN BENBROOK, *CEO*, MMG Inc., a full-service patient recruitment and retention group. For more information, visit wegetpatients.com.

NANCY L. BOMAN, M.D., PH.D. *VP, Clinical Development and Regulatory Affairs*, Acucela Inc., a clinical-stage biotechnology company focused on developing new methods for treating blinding eye diseases. For more information, visit acucela.com.

PAUL BONI, *Chief Research Officer*, Grail Research, which combines strategic consulting with market research to provide organizations with accurate, succinct answers to their most important business questions. For more information, visit grailresearch.com.

KATHY BRONSHTEIN, *Senior VP, Chief Compliance Officer*, Sudler & Hennessey, a healthcare communications firm. For more information, visit sudler.com.

EDDIE CAFFREY, *Global Head, Phase I*, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com.

PATRICK CHASSAIGNE, *Director, Late Phase Solutions*, Medidata Solutions, a global provider of hosted clinical development solutions that enhance the efficiency of clinical development processes. For more information, visit mdsol.com.

CLARE COLLETTI, *VP and Managing Director, Global Commercialization*, inVentiv Advance Insights, the strategic planning and consultative arm of inVentiv Health. For more information, visit inventivhealth.com.

ALAN COPA, PHARM.D. *President, Clinical Operations*, Cetero Research, a CRO providing early-phase research services. For more information, visit cetero.com.

WILLIAM H. CROWN, PH.D. *President*, i3 Innovus, a provider of health economics and outcomes research and market informatics solutions. For more information, visit i3global.com.

STEPHEN CUTLER, PH.D. *Senior VP and Chief Operating Officer*, Kendle, a global CRO providing a full range of development services. For more information, visit kendle.com.

ED DAMP, *Chief Operating Officer*, BioPath Consulting LLC, a specialty company focusing on scientific and clinical training and education of the salesforce. For more information, visit biopathconsulting.com.

JAMIE DANANBERG, M.D. *Executive Director of Clinical Pharmacology*, Eli Lilly and Company, which is developing a growing portfolio of pharmaceutical products. For more information, visit lilly.com.

FRAN L. DEGRAZIO, *VP, Marketing and Strategic Business Development*, West Pharmaceutical Services Inc., a global provider of standard-setting systems and device components for parenterally administered medicines. For more information, visit westpharma.com.

JAMES DESANTI, *Founder and CEO*, PharmaVigilant, a clinical trial technology provider. For more information, visit pharmavigilant.com.

NATALIE DOUGLAS, *CEO*, Idis, which develops and implements prelaunch named patient programs. For more information, visit idispharma.com.

MURRAY DUCHARME, PHARM.D. *Chief Science Officer*, Cetero Research, a CRO specializing in early-phase research services. For more information, visit cetero.com.

JAMES D. ESINHART PH.D. *Executive VP, Global Biometrics & North America Business Unit*, Chiltern, a global CRO. For more information, visit chiltern.com.

DAVE EVANS, *Chief Information Officer*, Octagon Research Solutions Inc., a provider of software and services to the life-sciences industry. For more information, visit octagonresearch.com.

MARTHA FELLER, PH.D. *Global Executive VP, Operations*, i3 Research, a full-service, global CRO therapeutically focused on CNS, oncology, respira-

tory and infectious diseases, endocrinology and metabolic diseases, and cardiology. For more information, visit i3global.com.

TREVOR FITZPATRICK, *VP and General Manager, Medical Communications Services*, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com.

JENS OLIVER FUNK, M.D. *Senior VP and Global Head of TA Oncology*, EMD Serono Inc., an affiliate of Merck KGaA, is a U.S. biopharmaceutical company that specializes in neurodegenerative diseases, fertility, metabolic endocrinology, and oncology. For more information, visit emd-serono.com.

JEAN-JACQUES GARAUD, M.D. *Global Head, Pharmaceutical Research and Early Development*, Roche, research-focused healthcare company with combined strengths in pharmaceuticals and diagnostics. For more information, visit rocheusa.com.

CHIP GILLOOLY, *VP, Capital*, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com.

MARK A. GOLDBERG, M.D. *Chief Operating Officer*, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com.

JOHN R. HALL, *Global Medical Affairs, Epidemiology and Outcomes Research*, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com.

KEVIN HRUSOVSKY, *President and CEO*, Caliper Life Sciences, provides technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. For more information, visit caliperls.com.

NIGEL HUGHES, *Founder and Director*, Firecrest Clinical, a clinical technology organization that brings together experts in clinical trials, pharmacy, medicine, communications, and technology to create Web-hosted solutions. For more information, visit firecrestclinical.com.

LONI JAKUB, *Manager, ViewPoint Implementation Services*, Octagon Research Solutions Inc., a provider of software and services to the life-sci-

ences industry. For more information, visit octagonresearch.com.

THOMAS W. JONES, PH.D. *Senior Director, Toxicology and Pathology*, Eli Lilly and Company, which is developing a growing portfolio of pharmaceutical products. For more information, visit lilly.com.

R. SHANE KENNEDY. *Executive VP, Managing Director*, Sudler Digital, Sudler & Hennessey, a healthcare communications firm. For more information, visit sudler.com.

STEVE KENT. *President*, Perceptive Informatics, an e-clinical solutions provider and subsidiary of Parexel International Corp. For more information, visit perceptive.com.

DARSHAN KULKARNI, PHARM.D., ESQ. *Principal Attorney*, Kulkarni LLC, a law firm that advises pharmaceutical companies and their service providers on bringing their products to market. For more information, visit conformlaw.com.

LAURIE LUCAS. *Founder and Principal*, L3 Healthcare Marketing, a strategic healthcare communications and marketing company specializing in market conditioning for novel products and technologies. For more information, visit l3hm.com.

HOWARD MAYER, M.D. *Chief Medical Officer*, EMD Serono Inc., an affiliate of Merck KGaA, is a U.S. biopharmaceutical company that specializes in neurodegenerative diseases, fertility, metabolic endocrinology, and oncology. For more information, visit emdserono.com.

TROY MCCALL, PH.D. *CEO*, Cetero Research, a CRO providing early-phase research services. For more information, visit cetero.com.

KALPANA MERCHANT, PH.D. *Chief Scientific Officer, the Translational Science Group*, Eli Lilly and Company, which is developing a growing portfolio of pharmaceutical products. For more information, visit lilly.com.

DONNA MICHALIZYSEN. *Managing Partner*, Precept Medical Communications, a healthcare education and communications company and a Sudler & Hennessey/WPP company. For more information, e-mail donna.michalizysen@preceptmedical.com.

MICHELLE MIDDLE, MB CH.B. *Corporate VP and Worldwide Head of Early Phase*, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com.

DOREEN MORAN. *Senior Digital Strategist*, Sudler Digital, Sudler & Hennessey, a healthcare communications firm. For more information, visit sudler.com.

MARIO R. NACINOVICH JR. *Managing Director*, Axon Communications, a specialist healthcare consulting firm, and Editor-in-Chief, Journal of Communication in Healthcare. For more information, visit axon-com.com or maney.co.uk/index.php/journals/cih.

MICHAEL NAIMOLI. *U.S. Life Sciences Industry Solutions Director*, Microsoft Corp., a global technology company. For more information, visit microsoft.com.

ROBERT A. NORRIS. *Founder and President*, Complete Healthcare Communications Inc., a strategic medical communications agency that specializes in publication planning. For more information, visit chcinc.com.

MICHAEL PARISI. *President*, Altum, a Common-Health freestanding, full-service, professional advertising and promotion company with global reach, spanning every marketing discipline with a focus on high-science and specialty markets. For more information, visit commonhealth.com.

BRIAN SANDERSON, M.D. *Medical Director*, Chiltern Early Phase, a global CRO. For more information, visit chiltern.com.

KERRI A. SCHOEDEL, PH.D. *Scientific Director, Clinical Pharmacology*, Kendle, a global CRO providing the full range of development services. For more information, visit kendle.com.

DAVID SELKIRK. *Senior Director*, Clinimetrics, a global full-service CRO that supports the complete spectrum of clinical trials. For more information, visit clinimetrics.com.

NANCY SMERKANICH. *Executive VP, Global Regulatory Affairs*, Octagon Research Solutions, a provider of software and services to the life-sciences industry. For more information, visit octagonresearch.com.

PETER SMITH, PH.D. *Senior VP, Nonclinical Development Sciences*, Millennium: The Takeda Oncology Company, biopharmaceutical company focused exclusively in oncology to improve the treatment of cancer around the world. For more information visit millennium.com.

SEAN SMITH. *VP, Logistics and Asia*, Fisher Clinical Services, provides products and services to support supply-chain needs within a clinical-trial

setting. For more information, visit fisherclinicalservices.com.

NAGARAJA SRIVATSAN. *VP and Head of Life Sciences, North America*, Cognizant, a provider of consulting, technology, and business process outsourcing services. For more information, visit cognizant.com.

ALAIN STRICKER-KRONGRAD, PH.D. *Chief Scientific Officer*, Charles River, which provides essential products and services to help pharmaceutical and biotechnology companies accelerate their research and drug development efforts. For more information, visit criver.com.

BARBARA TARDIFF, M.D. *Corporate VP*, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com.

ANNE TOMALIN. *President*, i3 CanReg, provides regulatory affairs consulting for the pharmaceutical, biotechnology, and medical-device industries. For more information, visit i3global.com.

SCOTT TREIBER. *Executive VP, Clinical Development Solutions*, inVentiv Clinical Solutions, which provides clinical trial management and monitoring, biostatistics, and data management solutions; regulatory consulting and liaison services; and patient and investigator recruitment, complemented by industry-leading staffing capabilities. For more information, visit inventivclinical.com.

JEFF TROTTER. *Executive VP - Phase IV Development*, PharmaNet, a global drug development services company that provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical-device industries. For more information, visit pharmanet.com.

CYNTHIA VERST, PHARM.D. *Senior VP, Late Phase Research*, i3 Innovus, a provider of health economics and outcomes research and market informatics solutions. For more information, visit i3global.com.

ROBIN L. WINTER-SPERRY, M.D. *President and CEO*, Scientific Advantage LLC, consulting firm specializing in medical affairs, medical information, and medical science liaison teams, and Science Oriented Solutions (SOS), a full-service contract MSL company. For more information, visit scientificadvantage.com or scienceoriented-solutions.com.

STUART YOUNG. *Executive VP, Clinical Monitoring*, Chiltern, a global CRO. For more information, visit chiltern.com.